OBJECTIVES
To compare the segment-based diagnostic performance of multiparametric magnetic resonance imaging (mpMRI), Gallium-68-prostate-specific membrane antigen-positron emission tomography/computed tomography (68Ga-PSMA-PET/CT), for detecting histopathologically confirmed prostate cancer (PCa).
PATIENTS AND METHO...
C. J. Schmidt, M. Bernhardt, Glen Kristiansen et al.· BJU International· 0 citations
Peptide receptor radionuclide therapy (PRRT) with ¹⁷⁷Lu-DOTATATE improves outcomes in neuroendocrine tumors (NETs), yet durable disease control remains limited in progressive pancreatic NET (pNET) and higher-grade disease. Combinations that enhance PRRT efficacy may be advantageous. As sunitinib has radiosensitizing an...
M. Essler, Nadine Veit, Aurelia Müller et al.· Cell Death Discovery· 0 citations
PURPOSE
[177Lu]Lu-PSMA-617 is a standard-of-care therapy for metastatic castration-resistant prostate cancer (mCRPC). Given the heterogeneous clinical responses, accessible prognostic tools are needed. We recently demonstrated that the Bellmunt Risk Score (BRS)-comprising ECOG performance status >0, hemoglobin <10 g/dL...
T. Büttner, Mike Wenzel, Philipp Mandel et al.· European Journal of Nuclear...· 0 citations
Background Magnetic resonance-guided focused ultrasound (MRgFUS) thalamotomy alleviates tremor in tremor-dominant Parkinson's disease (TD-PD). However, its effects on the functional network topology remain unclear. Methods Twenty-one TD-PD patients underwent unilateral MRgFUS thalamotomy and clinical and MRI assessment...
Jin-Long Liu, V. Purrer, J. Krauss et al.· NeuroImage: Clinical· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.